2nsd
From Proteopedia
(New page: 200px<br /><applet load="2nsd" size="350" color="white" frame="true" align="right" spinBox="true" caption="2nsd, resolution 1.9Å" /> '''Enoyl acyl carrier pr...) |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
| - | InhA, the enoyl acyl carrier protein reductase (ENR) from Mycobacterium | + | InhA, the enoyl acyl carrier protein reductase (ENR) from Mycobacterium tuberculosis, is one of the key enzymes involved in the type II fatty acid biosynthesis pathway of M. tuberculosis. We report here the discovery, through high-throughput screening, of a series of arylamides as a novel class of potent InhA inhibitors. These direct InhA inhibitors require no mycobacterial enzymatic activation and thus circumvent the resistance mechanism to antitubercular prodrugs such as INH and ETA that is most commonly observed in drug-resistant clinical isolates. The crystal structure of InhA complexed with one representative inhibitor reveals the binding mode of the inhibitor within the InhA active site. Further optimization through a microtiter synthesis strategy followed by in situ activity screening led to the discovery of a potent InhA inhibitor with in vitro IC(50)=90 nM, representing a 34-fold potency improvement over the lead compound. |
==About this Structure== | ==About this Structure== | ||
| Line 16: | Line 16: | ||
[[Category: Alian, A.]] | [[Category: Alian, A.]] | ||
[[Category: He, X.]] | [[Category: He, X.]] | ||
| - | [[Category: Montellano, P | + | [[Category: Montellano, P R.Ortiz de.]] |
[[Category: 4PI]] | [[Category: 4PI]] | ||
[[Category: NAD]] | [[Category: NAD]] | ||
| Line 24: | Line 24: | ||
[[Category: oxidoreductase]] | [[Category: oxidoreductase]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:10:25 2008'' |
Revision as of 16:10, 21 February 2008
|
Enoyl acyl carrier protein reductase InhA in complex with N-(4-methylbenzoyl)-4-benzylpiperidine
Overview
InhA, the enoyl acyl carrier protein reductase (ENR) from Mycobacterium tuberculosis, is one of the key enzymes involved in the type II fatty acid biosynthesis pathway of M. tuberculosis. We report here the discovery, through high-throughput screening, of a series of arylamides as a novel class of potent InhA inhibitors. These direct InhA inhibitors require no mycobacterial enzymatic activation and thus circumvent the resistance mechanism to antitubercular prodrugs such as INH and ETA that is most commonly observed in drug-resistant clinical isolates. The crystal structure of InhA complexed with one representative inhibitor reveals the binding mode of the inhibitor within the InhA active site. Further optimization through a microtiter synthesis strategy followed by in situ activity screening led to the discovery of a potent InhA inhibitor with in vitro IC(50)=90 nM, representing a 34-fold potency improvement over the lead compound.
About this Structure
2NSD is a Single protein structure of sequence from Mycobacterium tuberculosis with and as ligands. Active as [acyl-carrier-protein_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number 1.3.1.9 Full crystallographic information is available from OCA.
Reference
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides., He X, Alian A, Ortiz de Montellano PR, Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15. PMID:17723305 [[Category: Enoyl-[acyl-carrier-protein] reductase (NADH)]]
Page seeded by OCA on Thu Feb 21 18:10:25 2008
